The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.

"Declarations Ethics approval and consent to participateAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Research Ethics Committee of Sun Yat-sen University Cancer Center and the need of informed consent for this study was exempted in the ethical approval documents. (approval number: B2019-109). Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by grants from the National Natural Science Foundation of China [grant numbers: 81871971, 82073159, 82102873]."